Anish John

Mr. Anish John

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2022 in Gels
Verified
Journal Article
Open access
PDF file
MKMarina Koland
Marina Koland
Anoop Narayanan VAnoop Narayanan V
Anoop Narayanan V
AJAnish John
Anish John
ARArunraj Tharamelveliyil Rajendran
Arunraj Tharamelveliyil Rajendran
IRIndu Raghunath
Indu Raghunath
The intra-articular administration of conventional drug solutions or dispersions in joint diseases such as osteoarthritis has a relatively short retention time and, therefore, limited therapeutic effect. Thermosensitive polymer solutions that exhibit a sol–gel phase transition near body temperature after injection can prolong drug retention by providing a depot from which the drug release is sustained while relieving inflammation and preventing degradation of the joint complex. Thermosensitive hydrogels have in recent times garnered considerable attention in the intra-articular therapeutics of joint diseases such as osteoarthritis. Among the stimuli-responsive gelling systems, most research has focused on thermosensitive hydrogels. These gels are preferred over other stimuli-sensitive hydrogels since they have well-controlled in situ gelling properties and are also easier to load with drugs. Temperature-sensitive polymers, such as block copolymers or poloxamers, are frequently used to modify their gelation properties, usually in combination with other polymers. They are compatible with most drugs but may pose formulation challenges in terms of their low-response time, highly fragile nature, and low biocompatibility. The stability and biodegradability of implant hydrogels can control the drug release rate and treatment efficacy. This review stresses the application of thermosensitive gels in joint disorders and summarizes recent developments for intra-articular application, including the incorporation of nanoparticles. The hydrogel composition, drug release mechanisms, and the challenges involved in their formulation and storage are also discussed.

11 September 2024 in Precision Radiation Oncology
Verified
Journal Article
Open access
TVTreesa P. Varghese
Treesa P. Varghese
AJAnish John
Anish John
JMJithin Mathew
Jithin Mathew
Radiopharmaceutical therapy (RPT) is a precision medicine approach that involves the targeted delivery of radioactive atoms to tumor cells, representing a breakthrough strategy for cancer treatment. Radiopharmaceuticals typically consist of a small amount of radioactive material, a radionuclide, paired with a chemical that specifically targets the cell. Some radionuclides naturally target specific cells or biological processes without the need for modification. RPT is a novel cancer treatment method that offers various advantages over current traditional treatment approaches. One of the primary advantages of RPT is its ability to target cancer cells, including those in metastatic areas. Another key advantage of RPT is that radiation can be delivered systemically, locally, or physiologically to specific cells internally rather than being applied externally. Moreover, radiotracer imaging can be utilized to determine radiopharmaceutical absorption in target tissues before providing a therapeutic dose. Compared to all other cancer treatment approaches, RPT has demonstrated high efficacy with minimal toxicity. The recent approval of multiple RPT medicines by the US Food and Drug Administration highlights the tremendous potential of this treatment. This article provides a detailed review of RPT, including insights into manufacturing procedures, safety measures, and its applications in cancer therapy.

28 November 2022 in Journal of Health and Allied Sciences NU
Verified
Journal Article
Open access
PDF file
Anoop Narayanan VAnoop Narayanan V
Anoop Narayanan V
ASAnkitha Sharma
Ankitha Sharma
RSRajesh K. S.
Rajesh K. S.
ARArunraj Tharamelveliyil Rajendran
Arunraj Tharamelveliyil Rajendran
GPGururaj M. P.
Gururaj M. P.
AJAnish John
Anish John
The Indian system of medicine, Ayurveda employs Bacopa monnieri extract (BME) for memory enhancement. This study attempts to prepare and test a more potent formulation by incorporating BME in nanovesicles. BME-loaded liposomes and bilosomes (bile salt-stabilized liposomes) were formulated using soy phosphatidylcholine. Liposomes and bilosomes had homogeneous size distribution and an average size of 285.7 nm and 84 nm, respectively, with satisfactory zeta potential. Spherical multilamellar bilosomes and unilamellar liposomes were observed under transmission electron microscope (TEM), with BME entrapment efficiency of 85% and 45%, respectively. During a 72 h interval, bilosomes and liposomes released 78% and 65% of the loaded BME, exhibiting a biphasic release, following the Higuchi model diffusion. Both liposomes and bilosomes were stable in simulated gastric and intestinal fluids. When tested on dementia-induced Swiss albino mouse models using the Y-maze apparatus, the bilosome-treated group showed significant cognition enhancement activity than those treated with liposomal vesicles. The better pharmacological effect shown by bilosomes may be attributed to better bioavailability, possibly augmented by higher entrapment efficiency, and improved vesicle integrity afforded by bile salts. Likewise, bilosomes were more stable than liposomes in simulated gastric and intestinal fluids. Taken together, innovative formulation techniques hold substantial promise for enhancing the ethnopharmacological claims of BME.

9 July 2026 in Foods
Verified
Journal Article
Open access
PDF file
NANiyaz Ali-Haneef
Niyaz Ali-Haneef
AMAmar R. Mohite
Amar R. Mohite
PMPunitha Muruganantham
Punitha Muruganantham
ASAdhil Anver Salim
Adhil Anver Salim
KCKhanita Suman Chinannai
Khanita Suman Chinannai
Dr Inamul Hasan Hasan MadarDr Inamul Hasan Hasan Madar
Dr Inamul Hasan Hasan Madar
Postbiotics—defined by the International Scientific Association of Probiotics and Prebiotics (ISAPP) as preparations of inanimate microorganisms and/or their components that confer a health benefit to the host—are attractive from a stability perspective compared to live probiotics. They withstand thermal processing and room-temperature transport and storage and are compatible with low-pH or low-water-activity food products. Despite the promise, the literature is scattered, with no review that integrates evidence from the development pipeline. This review fills that gap. The ISAPP 2021 definition is reviewed, including the practical difficulty resulting from the exclusion of cell-free supernatant (CFS)-based products that represent most of the experimental evidence. Fermentation-based production systems and non-thermal inactivation technologies—high-pressure processing (HPP), pulsed electric fields (PEF), ultrasound, cold plasma, and supercritical CO2—are compared; non-thermal inactivation preserves the activity of thermolabile bacteriocins and phenolic fractions. Delivery systems such as spray-drying, alginate hydrogel microencapsulation, liposomal nanoencapsulation, and carboxymethyl cellulose (CMC) active packaging are assessed for gastrointestinal survival and food system compatibility. Biopreservation potential is reviewed in meat, seafood, dairy, fresh produce, and fermented foods. The regulatory framework for the United States, European Union, Japan, and India is critically reviewed; “postbiotic” is not an explicitly defined term in 2025. Three priority translational bottlenecks are identified: the absence of standardized potency assays, the lack of cross-class quality benchmarks, and the unresolved conflict between heat-inactivated dairy postbiotics and the Codex Alimentarius live-culture standard. Harmonized regulations and characterization standards are critical needs for postbiotic functional food development.

13 October 2021 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
AJAnish John
Anish John
Anoop Narayanan VAnoop Narayanan V
Anoop Narayanan V
KKKiran Konkodi
Kiran Konkodi

7 November 2024 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
Anoop Narayanan VAnoop Narayanan V
Anoop Narayanan V
AJAnish John
Anish John
SRSumukh P. R.
Sumukh P. R.
SPSneh Priya
Sneh Priya
CRChaithra Raviraj
Chaithra Raviraj
HAHarsha Ashtekar
Harsha Ashtekar
Objective: This study aimed to enhance the oral bioavailability of Ipriflavone (IP) and evaluate its osteogenic effect on human osteosarcoma cells (MG-63) by developing Ipriflavone-loaded Solid Lipid Nanoparticles (IP-SLN). Methods: IP-SLNs were prepared using a modified solvent evaporation method with probe sonication. Formulation optimization employed Central Composite Design (CCD) with independent variables, including lipid amount, surfactant concentration, and sonication time. Characterization was performed using Transmission Electron Microscopy (TEM). In vitro drug release and ex vivo permeation studies were conducted to assess drug release kinetics and bioavailability. Cytotoxicity, Alkaline Phosphatase (ALP) activity, and calcium deposition studies on MG-63 cells evaluated osteogenic effects. Results: TEM images showed round particles with an average diameter of 43.24±3 nm, a zeta potential of-9.53 mV, and a drug entrapment efficiency of 76.53±1.84%. In vitro drug release from IP-SLN was 79.02% compared to 14.21% from IP after 48 h, following the Korsmeyer-Peppas model and first-order kinetics. Ex vivo permeation of IP-SLN was approximately 2-fold higher than IP dispersion. Cytotoxicity studies revealed no toxicity on MG-63 cells. ALP activity and calcium deposition studies indicated that IP-SLN stimulated osteoblast differentiation, increasing alkaline phosphatase activity and mineralization. Pharmacokinetic studies demonstrated that IP-SLN increased the relative bioavailability by 515% compared to ipriflavone. Conclusion: IP-SLN formulations significantly improved the oral bioavailability and osteogenic effects of ipriflavone on MG-63 cells, suggesting potential for novel therapeutic applications in osteoporosis treatment.